Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis
To define prognostic factors for breast cancer patients with brain metastases, compare their clinical courses and prognoses according to breast cancer subtypes, and analyze the causes of death in such patients. We retrospectively analyzed 1,466 patients diagnosed with brain metastases between April...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2014-08, Vol.147 (1), p.103-112 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 112 |
|---|---|
| container_issue | 1 |
| container_start_page | 103 |
| container_title | Breast cancer research and treatment |
| container_volume | 147 |
| creator | Niikura, Naoki Hayashi, Naoki Masuda, Norikazu Takashima, Seiki Nakamura, Rikiya Watanabe, Ken-ichi Kanbayashi, Chizuko Ishida, Mayumi Hozumi, Yasuo Tsuneizumi, Michiko Kondo, Naoto Naito, Yoichi Honda, Yayoi Matsui, Akira Fujisawa, Tomomi Oshitanai, Risa Yasojima, Hiroyuki Tokuda, Yutaka Saji, Shigehira Iwata, Hiroji |
| description | To define prognostic factors for breast cancer patients with brain metastases, compare their clinical courses and prognoses according to breast cancer subtypes, and analyze the causes of death in such patients. We retrospectively analyzed 1,466 patients diagnosed with brain metastases between April 1, 2001 and December 31, 2012, from 24 institutions of the Japan Clinical Oncology Group. Overall, 1,256 patients with brain metastases were included. The median overall survival (OS) was 8.7 months (95 % confidence interval [CI] 7.8–9.6 months). Univariate and multivariate analyses revealed that patients diagnosed with brain metastasis within 6 months of metastatic breast cancer diagnoses, asymptomatic brain disease, or HER2-positive/estrogen receptor-positive tumors had increased OS. Median OS after the development of brain metastases was 9.3 months (95 % CI 7.2–11.3) for the luminal type, 16.5 months (95 % CI 11.9–21.1) for the luminal-HER2 type, 11.5 months (95 % CI 9.1–13.8) for the HER2 type, and 4.9 months (95 % CI 3.9–5.9) for the triple-negative type. Luminal-HER2 type patients had significantly longer OS than patients with the luminal type (hazard ratio [HR] = 1.50,
P
|
| doi_str_mv | 10.1007/s10549-014-3090-8 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1553317525</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A434426595</galeid><sourcerecordid>A434426595</sourcerecordid><originalsourceid>FETCH-LOGICAL-c638t-4888dd63bdf8efc646901498d43ac4002b586d0b35da261f39536e7ba0ff60b3</originalsourceid><addsrcrecordid>eNqNkl1rFDEUhgdR7Fr9Ad5IQBBvpiaTj5l4V4pfUPCm9yGTOdlNmZmsScayP8T_61m36la0SAIhJ8_7nuTkVNVzRs8Ype2bzKgUuqZM1JxqWncPqhWTLa_bhrUPqxVlqq1VR9VJ9STna0qpbql-XJ00klGlFFtV364S2DLBXEhciosTZGLngWxTXM8xl-CIt67ElImPiWxtCchmchPKhvTJhplMUGzGiUqf4oRRwD1xdnaQSPQErNuQvPRlt4W3xJJpGdEXbfA4QUkxb8GV8BUwsx13OeSn1SNvxwzPbtfT6ur9u6uLj_Xl5w-fLs4va6d4V2rRdd0wKN4PvgPvlFAaa6G7QXDrBKVNLzs10J7LwTaKea4lV9D2lnqvMHxavT7Y4mu_LJCLmUJ2MI52hrhkw6TknLWykYi-_AO9jkvC6_6gmlYzofhvam1HMGH2sSTr9qbmXHAhGiW1vJfindRaK6GROvsLhWOAKbg4gw8Yv2P7X4LjDK-OBBuwY9nkOC4lxDnfdb4XPHZkB9Dhp-YE3mxTmGzaGUbNvmXNoWUNfpPZt6zpUPPitrJLP8HwS_GzRxFoDkDGo3kN6aj0_3T9DhY19Mw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1552791463</pqid></control><display><type>article</type><title>Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Niikura, Naoki ; Hayashi, Naoki ; Masuda, Norikazu ; Takashima, Seiki ; Nakamura, Rikiya ; Watanabe, Ken-ichi ; Kanbayashi, Chizuko ; Ishida, Mayumi ; Hozumi, Yasuo ; Tsuneizumi, Michiko ; Kondo, Naoto ; Naito, Yoichi ; Honda, Yayoi ; Matsui, Akira ; Fujisawa, Tomomi ; Oshitanai, Risa ; Yasojima, Hiroyuki ; Tokuda, Yutaka ; Saji, Shigehira ; Iwata, Hiroji</creator><creatorcontrib>Niikura, Naoki ; Hayashi, Naoki ; Masuda, Norikazu ; Takashima, Seiki ; Nakamura, Rikiya ; Watanabe, Ken-ichi ; Kanbayashi, Chizuko ; Ishida, Mayumi ; Hozumi, Yasuo ; Tsuneizumi, Michiko ; Kondo, Naoto ; Naito, Yoichi ; Honda, Yayoi ; Matsui, Akira ; Fujisawa, Tomomi ; Oshitanai, Risa ; Yasojima, Hiroyuki ; Tokuda, Yutaka ; Saji, Shigehira ; Iwata, Hiroji</creatorcontrib><description>To define prognostic factors for breast cancer patients with brain metastases, compare their clinical courses and prognoses according to breast cancer subtypes, and analyze the causes of death in such patients. We retrospectively analyzed 1,466 patients diagnosed with brain metastases between April 1, 2001 and December 31, 2012, from 24 institutions of the Japan Clinical Oncology Group. Overall, 1,256 patients with brain metastases were included. The median overall survival (OS) was 8.7 months (95 % confidence interval [CI] 7.8–9.6 months). Univariate and multivariate analyses revealed that patients diagnosed with brain metastasis within 6 months of metastatic breast cancer diagnoses, asymptomatic brain disease, or HER2-positive/estrogen receptor-positive tumors had increased OS. Median OS after the development of brain metastases was 9.3 months (95 % CI 7.2–11.3) for the luminal type, 16.5 months (95 % CI 11.9–21.1) for the luminal-HER2 type, 11.5 months (95 % CI 9.1–13.8) for the HER2 type, and 4.9 months (95 % CI 3.9–5.9) for the triple-negative type. Luminal-HER2 type patients had significantly longer OS than patients with the luminal type (hazard ratio [HR] = 1.50,
P
< 0.0001) and triple-negative type (HR = 1.97,
P
< 0.0001); no significant differences were noted compared to HER2-type patients (HR = 1.19,
P
= 0.117). The prognosis and clinical course of patients with brain metastasis from breast cancer before and after developing brain metastases vary according to subtype. Focusing on the subtypes of breast cancer can optimize the prevention, early detection, and improved treatment of brain metastases.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-014-3090-8</identifier><identifier>PMID: 25106661</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Brain ; Brain Neoplasms - mortality ; Brain Neoplasms - secondary ; Brain Neoplasms - therapy ; Breast cancer ; Breast Neoplasms - classification ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Cancer metastasis ; Cancer patients ; Cancer research ; Cancer therapies ; Care and treatment ; Clinical Trial ; Combined Modality Therapy ; Development and progression ; Epidermal growth factor ; Female ; Follow-Up Studies ; Humans ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metastasis ; Middle Aged ; Neoplasm Grading ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - therapy ; Neoplasm Staging ; Oncology ; Patient outcomes ; Prognosis ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Retrospective Studies ; Survival Rate</subject><ispartof>Breast cancer research and treatment, 2014-08, Vol.147 (1), p.103-112</ispartof><rights>Springer Science+Business Media New York 2014</rights><rights>COPYRIGHT 2014 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c638t-4888dd63bdf8efc646901498d43ac4002b586d0b35da261f39536e7ba0ff60b3</citedby><cites>FETCH-LOGICAL-c638t-4888dd63bdf8efc646901498d43ac4002b586d0b35da261f39536e7ba0ff60b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-014-3090-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-014-3090-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25106661$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Niikura, Naoki</creatorcontrib><creatorcontrib>Hayashi, Naoki</creatorcontrib><creatorcontrib>Masuda, Norikazu</creatorcontrib><creatorcontrib>Takashima, Seiki</creatorcontrib><creatorcontrib>Nakamura, Rikiya</creatorcontrib><creatorcontrib>Watanabe, Ken-ichi</creatorcontrib><creatorcontrib>Kanbayashi, Chizuko</creatorcontrib><creatorcontrib>Ishida, Mayumi</creatorcontrib><creatorcontrib>Hozumi, Yasuo</creatorcontrib><creatorcontrib>Tsuneizumi, Michiko</creatorcontrib><creatorcontrib>Kondo, Naoto</creatorcontrib><creatorcontrib>Naito, Yoichi</creatorcontrib><creatorcontrib>Honda, Yayoi</creatorcontrib><creatorcontrib>Matsui, Akira</creatorcontrib><creatorcontrib>Fujisawa, Tomomi</creatorcontrib><creatorcontrib>Oshitanai, Risa</creatorcontrib><creatorcontrib>Yasojima, Hiroyuki</creatorcontrib><creatorcontrib>Tokuda, Yutaka</creatorcontrib><creatorcontrib>Saji, Shigehira</creatorcontrib><creatorcontrib>Iwata, Hiroji</creatorcontrib><title>Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>To define prognostic factors for breast cancer patients with brain metastases, compare their clinical courses and prognoses according to breast cancer subtypes, and analyze the causes of death in such patients. We retrospectively analyzed 1,466 patients diagnosed with brain metastases between April 1, 2001 and December 31, 2012, from 24 institutions of the Japan Clinical Oncology Group. Overall, 1,256 patients with brain metastases were included. The median overall survival (OS) was 8.7 months (95 % confidence interval [CI] 7.8–9.6 months). Univariate and multivariate analyses revealed that patients diagnosed with brain metastasis within 6 months of metastatic breast cancer diagnoses, asymptomatic brain disease, or HER2-positive/estrogen receptor-positive tumors had increased OS. Median OS after the development of brain metastases was 9.3 months (95 % CI 7.2–11.3) for the luminal type, 16.5 months (95 % CI 11.9–21.1) for the luminal-HER2 type, 11.5 months (95 % CI 9.1–13.8) for the HER2 type, and 4.9 months (95 % CI 3.9–5.9) for the triple-negative type. Luminal-HER2 type patients had significantly longer OS than patients with the luminal type (hazard ratio [HR] = 1.50,
P
< 0.0001) and triple-negative type (HR = 1.97,
P
< 0.0001); no significant differences were noted compared to HER2-type patients (HR = 1.19,
P
= 0.117). The prognosis and clinical course of patients with brain metastasis from breast cancer before and after developing brain metastases vary according to subtype. Focusing on the subtypes of breast cancer can optimize the prevention, early detection, and improved treatment of brain metastases.</description><subject>Brain</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - secondary</subject><subject>Brain Neoplasms - therapy</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - classification</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer metastasis</subject><subject>Cancer patients</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Clinical Trial</subject><subject>Combined Modality Therapy</subject><subject>Development and progression</subject><subject>Epidermal growth factor</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Patient outcomes</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkl1rFDEUhgdR7Fr9Ad5IQBBvpiaTj5l4V4pfUPCm9yGTOdlNmZmsScayP8T_61m36la0SAIhJ8_7nuTkVNVzRs8Ype2bzKgUuqZM1JxqWncPqhWTLa_bhrUPqxVlqq1VR9VJ9STna0qpbql-XJ00klGlFFtV364S2DLBXEhciosTZGLngWxTXM8xl-CIt67ElImPiWxtCchmchPKhvTJhplMUGzGiUqf4oRRwD1xdnaQSPQErNuQvPRlt4W3xJJpGdEXbfA4QUkxb8GV8BUwsx13OeSn1SNvxwzPbtfT6ur9u6uLj_Xl5w-fLs4va6d4V2rRdd0wKN4PvgPvlFAaa6G7QXDrBKVNLzs10J7LwTaKea4lV9D2lnqvMHxavT7Y4mu_LJCLmUJ2MI52hrhkw6TknLWykYi-_AO9jkvC6_6gmlYzofhvam1HMGH2sSTr9qbmXHAhGiW1vJfindRaK6GROvsLhWOAKbg4gw8Yv2P7X4LjDK-OBBuwY9nkOC4lxDnfdb4XPHZkB9Dhp-YE3mxTmGzaGUbNvmXNoWUNfpPZt6zpUPPitrJLP8HwS_GzRxFoDkDGo3kN6aj0_3T9DhY19Mw</recordid><startdate>20140801</startdate><enddate>20140801</enddate><creator>Niikura, Naoki</creator><creator>Hayashi, Naoki</creator><creator>Masuda, Norikazu</creator><creator>Takashima, Seiki</creator><creator>Nakamura, Rikiya</creator><creator>Watanabe, Ken-ichi</creator><creator>Kanbayashi, Chizuko</creator><creator>Ishida, Mayumi</creator><creator>Hozumi, Yasuo</creator><creator>Tsuneizumi, Michiko</creator><creator>Kondo, Naoto</creator><creator>Naito, Yoichi</creator><creator>Honda, Yayoi</creator><creator>Matsui, Akira</creator><creator>Fujisawa, Tomomi</creator><creator>Oshitanai, Risa</creator><creator>Yasojima, Hiroyuki</creator><creator>Tokuda, Yutaka</creator><creator>Saji, Shigehira</creator><creator>Iwata, Hiroji</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20140801</creationdate><title>Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis</title><author>Niikura, Naoki ; Hayashi, Naoki ; Masuda, Norikazu ; Takashima, Seiki ; Nakamura, Rikiya ; Watanabe, Ken-ichi ; Kanbayashi, Chizuko ; Ishida, Mayumi ; Hozumi, Yasuo ; Tsuneizumi, Michiko ; Kondo, Naoto ; Naito, Yoichi ; Honda, Yayoi ; Matsui, Akira ; Fujisawa, Tomomi ; Oshitanai, Risa ; Yasojima, Hiroyuki ; Tokuda, Yutaka ; Saji, Shigehira ; Iwata, Hiroji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c638t-4888dd63bdf8efc646901498d43ac4002b586d0b35da261f39536e7ba0ff60b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Brain</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - secondary</topic><topic>Brain Neoplasms - therapy</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - classification</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer metastasis</topic><topic>Cancer patients</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Clinical Trial</topic><topic>Combined Modality Therapy</topic><topic>Development and progression</topic><topic>Epidermal growth factor</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Patient outcomes</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niikura, Naoki</creatorcontrib><creatorcontrib>Hayashi, Naoki</creatorcontrib><creatorcontrib>Masuda, Norikazu</creatorcontrib><creatorcontrib>Takashima, Seiki</creatorcontrib><creatorcontrib>Nakamura, Rikiya</creatorcontrib><creatorcontrib>Watanabe, Ken-ichi</creatorcontrib><creatorcontrib>Kanbayashi, Chizuko</creatorcontrib><creatorcontrib>Ishida, Mayumi</creatorcontrib><creatorcontrib>Hozumi, Yasuo</creatorcontrib><creatorcontrib>Tsuneizumi, Michiko</creatorcontrib><creatorcontrib>Kondo, Naoto</creatorcontrib><creatorcontrib>Naito, Yoichi</creatorcontrib><creatorcontrib>Honda, Yayoi</creatorcontrib><creatorcontrib>Matsui, Akira</creatorcontrib><creatorcontrib>Fujisawa, Tomomi</creatorcontrib><creatorcontrib>Oshitanai, Risa</creatorcontrib><creatorcontrib>Yasojima, Hiroyuki</creatorcontrib><creatorcontrib>Tokuda, Yutaka</creatorcontrib><creatorcontrib>Saji, Shigehira</creatorcontrib><creatorcontrib>Iwata, Hiroji</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niikura, Naoki</au><au>Hayashi, Naoki</au><au>Masuda, Norikazu</au><au>Takashima, Seiki</au><au>Nakamura, Rikiya</au><au>Watanabe, Ken-ichi</au><au>Kanbayashi, Chizuko</au><au>Ishida, Mayumi</au><au>Hozumi, Yasuo</au><au>Tsuneizumi, Michiko</au><au>Kondo, Naoto</au><au>Naito, Yoichi</au><au>Honda, Yayoi</au><au>Matsui, Akira</au><au>Fujisawa, Tomomi</au><au>Oshitanai, Risa</au><au>Yasojima, Hiroyuki</au><au>Tokuda, Yutaka</au><au>Saji, Shigehira</au><au>Iwata, Hiroji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2014-08-01</date><risdate>2014</risdate><volume>147</volume><issue>1</issue><spage>103</spage><epage>112</epage><pages>103-112</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>To define prognostic factors for breast cancer patients with brain metastases, compare their clinical courses and prognoses according to breast cancer subtypes, and analyze the causes of death in such patients. We retrospectively analyzed 1,466 patients diagnosed with brain metastases between April 1, 2001 and December 31, 2012, from 24 institutions of the Japan Clinical Oncology Group. Overall, 1,256 patients with brain metastases were included. The median overall survival (OS) was 8.7 months (95 % confidence interval [CI] 7.8–9.6 months). Univariate and multivariate analyses revealed that patients diagnosed with brain metastasis within 6 months of metastatic breast cancer diagnoses, asymptomatic brain disease, or HER2-positive/estrogen receptor-positive tumors had increased OS. Median OS after the development of brain metastases was 9.3 months (95 % CI 7.2–11.3) for the luminal type, 16.5 months (95 % CI 11.9–21.1) for the luminal-HER2 type, 11.5 months (95 % CI 9.1–13.8) for the HER2 type, and 4.9 months (95 % CI 3.9–5.9) for the triple-negative type. Luminal-HER2 type patients had significantly longer OS than patients with the luminal type (hazard ratio [HR] = 1.50,
P
< 0.0001) and triple-negative type (HR = 1.97,
P
< 0.0001); no significant differences were noted compared to HER2-type patients (HR = 1.19,
P
= 0.117). The prognosis and clinical course of patients with brain metastasis from breast cancer before and after developing brain metastases vary according to subtype. Focusing on the subtypes of breast cancer can optimize the prevention, early detection, and improved treatment of brain metastases.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>25106661</pmid><doi>10.1007/s10549-014-3090-8</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2014-08, Vol.147 (1), p.103-112 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1553317525 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Brain Brain Neoplasms - mortality Brain Neoplasms - secondary Brain Neoplasms - therapy Breast cancer Breast Neoplasms - classification Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - therapy Cancer metastasis Cancer patients Cancer research Cancer therapies Care and treatment Clinical Trial Combined Modality Therapy Development and progression Epidermal growth factor Female Follow-Up Studies Humans Medical prognosis Medicine Medicine & Public Health Metastasis Middle Aged Neoplasm Grading Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - therapy Neoplasm Staging Oncology Patient outcomes Prognosis Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Retrospective Studies Survival Rate |
| title | Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T12%3A45%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20outcomes%20and%20prognostic%20factors%20for%20patients%20with%20brain%20metastases%20from%20breast%20cancer%20of%20each%20subtype:%20a%20multicenter%20retrospective%20analysis&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Niikura,%20Naoki&rft.date=2014-08-01&rft.volume=147&rft.issue=1&rft.spage=103&rft.epage=112&rft.pages=103-112&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-014-3090-8&rft_dat=%3Cgale_proqu%3EA434426595%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1552791463&rft_id=info:pmid/25106661&rft_galeid=A434426595&rfr_iscdi=true |